Pharmacoeconomic Analysis of Anti-VEGF Treatments in Patients With Neovascular Age-Related Macular Degeneration in Russia

Speaker(s)

Klabukova D1, Krysanova V2, Krysanov I3, Kurkin D3, Kolosov Y3, Ermakova V4, Makarova E5
1Russian University of Medicine, Moscow, MOW, Russia, 2Medical Institute of Continuing Education, BIOTECH University, Moscow, Russian Federation, 3Russian University of Medicine, Moscow, Russian Federation, 4Sechenov First Moscow State Medical University, Moscow, Russian Federation, 5Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

Presentation Documents

OBJECTIVES: The leading cause of visual impairment for elderly people in developed countries is age-related macular degeneration (AMD). Faricimab (FAR) is a novel antibody, targeting both angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A) pathological angiogenesis pathways in AMD. It is available from 2022, but comparative studies with other angiogenesis inhibitors are limited. The study aim was to conduct pharmacoeconomic analysis of using intravitreal injections (IVIs) of anti-VEGF drugs for patients with neovascular AMD (nAMD) in Russia.

METHODS: We analyzed published clinical trials to evaluate the comparative efficacy and safety of FAR 6 mg vs other registered in Russia first-line treatment options: ranibizumab (RAN) 0.5 mg, aflibercept (AFL) 2 mg. We developed MS Excel model for one patient with nAMD receiving medical care with anti-VEGF IVIs. Study designs were Cost Minimization Analysis and Budget Impact Analysis (BIA). The model time horizon was 2 years. Direct medical costs included drugs and specialized inpatient care from the Russian healthcare system perspective.

RESULTS: The efficacy and safety of FAR with IVIs up to once every 16 weeks is comparable to AFL and RAN in various fixed and treat-and-extend treatment regimens. FAR (n = 10) is associated with less IVIs frequency per 2 years compared with AFL (n = 15) and RAN (n = 19). FAR usage is associated with less treatment cost over 2 years with 50% reduction compared with AFL (€3,122.3 and €2,899.4 in 24-hour and day care hospital, respectively) and 90% reduction compared with RAN (€5,620.2 and €5,219.0 in 24-hour and day care hospital, respectively). Budget Impact Analysis demonstrated that increasing the share of FAR up to 40% would result in cost savings of €830,414,724.4 (10.71%) within 2 years (rate for June 1, 2024).

CONCLUSIONS: FAR treatment as first-line therapy is a clinically effective and cost-saving approach for patients with nAMD in Russia.

Code

EE219

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Insurance Systems & National Health Care, Trial-Based Economic Evaluation

Disease

Drugs, Geriatrics, Sensory System Disorders (Ear, Eye, Dental, Skin)